{"success":true,"data":{"pressRelease":{"id":"73280","rtpr_id":"nGNXPpfx","ticker":"MLSS","exchange":"NYSE American","all_tickers":["MLSS"],"title":"Milestone Scientific Strengthens Board to Support Next Phase of Growth","author":"Globe Newswire","published_at":"2026-06-25T13:00:00.845Z","article_body":"ROSELAND, N.J., June 25, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc.\n(NYSE: MLSS), a leading developer of computerized drug delivery instruments\nthat provide painless and precise injections, today announced a series of\nstrategic governance initiatives designed to support the Company’s continued\nevolution and long-term growth. These actions include strengthening the Board\nof Directors with two highly experienced independent directors, transitioning\nBoard leadership to support closer strategic execution and aligning with the\nCompany's founder through a restructured agreement that reinforces continuity\nand future focus.\n\nAs part of these initiatives, Benedetta I. Casamento has transitioned from\nChair of the Board to Executive Chair. In this expanded role, she will work\nclosely with the management team and the Board of Directors to provide\nstrategic guidance, support execution of the Company’s objectives and help\nposition Milestone Scientific for its next phase of growth and value creation.\n\nThe Company also announced the appointments of Greg Shilling and Kelly Ann\nUlto as independent members of its Board of Directors. Together, they bring\nextensive experience in healthcare technology, finance, corporate governance\nand strategic growth, further strengthening the Board with capabilities\naligned to the Company’s priorities.\n\n\"We have made meaningful progress in advancing our strategic and commercial\nobjectives, and these board enhancements position us well for the next stage\nof the Company’s evolution,\" said Eric Hines, Chief Executive Officer of\nMilestone Scientific. \"Benedetta’s transition to Executive Chair ensures\ncontinuity while enabling even greater strategic engagement with management.\nAt the same time, the addition of Kelly Ulto and Greg Shilling brings highly\nrelevant expertise that strengthens our governance and supports our focus on\ndisciplined execution and innovation.\"\n\nGreg Shilling\n\nMr. Shilling is a seasoned technology executive and entrepreneur with more\nthan 30 years of leadership experience across healthcare technology, software,\ninteroperability, artificial intelligence and cybersecurity. Throughout his\ncareer, Mr. Shilling has advised technology companies on growth strategy,\ninvestment and operational scaling.\n\nHe currently serves as Partner and General Manager of 121G and 10Bridge, where\nhe leads initiatives focused on digital transformation, software development,\ncybersecurity and data interoperability. Previously, he spent more than 17\nyears at Greenway Health in senior executive roles overseeing corporate\ndevelopment, strategic partnerships, enterprise sales and marketing. During\nhis tenure, he contributed to the company’s growth from an early-stage\nhealthcare technology provider to a leading electronic health record software\ncompany, including its involvement in public market activity, private equity\ntransactions, mergers and acquisitions and strategic partnerships. He holds a\nBachelor of Science in Finance from Auburn University.\n\nKelly Ann Ulto, CPA, MBA\n\nMs. Ulto is a Certified Public Accountant with more than 30 years of\nexperience in audit, financial reporting, internal controls and risk\noversight. She began her career at KPMG LLP, where she rose to Senior Manager\nin the Audit practice, leading client audit engagements and evaluating control\nenvironments while working closely with senior leadership and audit\ncommittees.\n\nSince 2004, Ms. Ulto has served as a Clinical Professor at Fordham\nUniversity’s Gabelli School of Business, where she teaches audit, analytics\nand financial reporting. She has maintained an active professional practice\nalongside her academic role, including delivering technical audit training to\nKPMG professionals nationwide for more than 15 years. She has also developed\nfraud detection training for the U.S. Securities and Exchange Commission,\ntrained FINRA examiners in financial accounting and financial statement\nanalysis and contributed to AICPA Industry Guides.\n\nMs. Ulto brings audit committee experience through her service on the Pelham\nUnion Free School District Audit Committee from 2017 to 2025, where she\nparticipated in audit planning, internal control oversight and financial\nreporting review. She previously served as Board Member and Treasurer of the\nPelham Art Center. Ms. Ulto holds an MBA in Information Decision Technology\nfrom Iona University and a Bachelor of Science in Public Accounting from\nFordham University.\n\nFounder Transition and Continued Advisory Role\n\nThe Company also announced that it has entered into a restructured agreement\nwith its founder Leonard (\"Len\") Osser, reflecting a collaborative transition\nthat supports the Company's governance evolution while aligning the interests\nof shareholders and the Company. As founder, former Chief Executive Officer\nand former Board member, Mr. Osser has played a pivotal role in establishing\nMilestone Scientific's vision and advancing its technology platform.\n\n\"We want to thank Len for his vision in founding Milestone Scientific and for\nhis many contributions as our Chief Executive Officer and member of the Board\nof Directors,\" Hines added. \"His leadership helped establish the foundation\nfor the Company and advance the innovative technology that continues to\ndifferentiate us today. We are pleased that Len will continue to support the\nCompany as an advisor and appreciate his willingness to restructure his prior\ncontractual arrangements in a manner that benefits our shareholders and\nprovides the Company with greater flexibility moving forward.”\n\nAdditional details regarding the board appointments and the agreement with Mr.\nOsser are included in the Company’s Current Report on Form 8-K filed with\nthe U.S. Securities and Exchange Commission.\n\nAbout Milestone Scientific Inc.\n\nMilestone Scientific Inc. (MLSS) is a technology-focused medical research and\ndevelopment company that patents, designs, and develops innovative injection\ntechnologies and instruments for medical and dental applications. Milestone\nScientific’s computer-controlled systems are designed to make injections\nprecise, efficient and increase the overall patient comfort and safety. Their\nproprietary DPS Dynamic Pressure Sensing Technology® instruments is the\nplatform to advance the development of next-generation devices, regulating\nflow rate and monitoring pressure from the tip of the needle, through platform\nextensions of subcutaneous drug delivery, including local anesthetic. To learn\nmore, view the MLSS brand video\n(https://www.globenewswire.com/Tracker?data=AI9u3tx5unpMxON3sgE7pFXSRe91g2Kslm8Qw7TrmfsvJWCV4pFAdA4NTrkJI_CK7QmI5JeEPk4214Yx_xBzJg7OofQ5DwuvQ-Aqe0y_-Xsr9j99kn5dEyzx-8ZdfEYaIt4Fyx9LH6xEmYe08Bn0Lg==)\nor visit milestonescientific.com\n(https://www.globenewswire.com/Tracker?data=7jdVnjfGppuK3yMIKoSZTSknJuXZX62NJOjbMTLW26LdV4IvVaYV1oXezaXzvOLUdJs53LfTqdu-ebbK3KZRhSZXCOAxEKMe7ICvlKiHwxOhgB4LGKDXCrFOVC-UsU2a).\n\nSafe Harbor Statement\n\nThis press release contains forward-looking statements regarding the timing\nand financial impact of Milestone’s ability to implement its business plan,\nexpected revenues, timing of regulatory approvals and future success. These\nstatements involve a number of risks and uncertainties and are based on\nassumptions involving judgments with respect to future economic, competitive\nand market conditions, future business decisions and regulatory developments,\nall of which are difficult or impossible to predict accurately and many of\nwhich are beyond Milestone’s control. Some of the important factors that\ncould cause actual results to differ materially from those indicated by the\nforward-looking statements are general economic conditions, failure to achieve\nexpected revenue growth, changes in our operating expenses, adverse patent\nrulings, FDA or legal developments, competitive pressures, changes in customer\nand market requirements and standards, and the risk factors detailed from time\nto time in Milestone’s periodic filings with the Securities and Exchange\nCommission, including without limitation, Milestone’s Annual Report for the\nyear ended December 31, 2025. The forward-looking statements in this press\nrelease are based upon management’s reasonable belief as of the date hereof.\nMilestone undertakes no obligation to revise or update publicly any\nforward-looking statements for any reason. Coding and payment decisions are\ndetermined solely by providers and payers based on applicable laws and\npolicies. Any potential Category I designation is determined solely by the\nAmerican Medical Association and is not guaranteed. Providers remain\nresponsible for compliance with all applicable billing, coding, and regulatory\nrequirements. Forward-looking case submission expectations, reimbursement\ntargets, and revenue estimates referenced herein are based on current program\nenrollment, advisor commitments, and historical payer activity, and are\nsubject to change based on clinical scheduling, payer processing timelines,\nregulatory developments, and other factors. There can be no assurance that\nCategory I designation, targeted reimbursement levels, or projected revenue\nlevels will be achieved.\n\nContact:\n\nHAYDEN IR:\nJames Carbonara\n(646)-755-7412\njames@haydenir.com\n\nBrett Maas\n(646) 536-7331\nbrett@haydenir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/408ad3c5-6ad3-41bd-9763-356666216796)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXPpfx","title":"Milestone Scientific Strengthens Board to Support Next Phase of Growth","author":"Globe Newswire","ticker":"MLSS","created":"2026-06-25T13:00:00.845Z","tickers":["MLSS"],"exchange":"NYSE American","article_body":"ROSELAND, N.J., June 25, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc.\n(NYSE: MLSS), a leading developer of computerized drug delivery instruments\nthat provide painless and precise injections, today announced a series of\nstrategic governance initiatives designed to support the Company’s continued\nevolution and long-term growth. These actions include strengthening the Board\nof Directors with two highly experienced independent directors, transitioning\nBoard leadership to support closer strategic execution and aligning with the\nCompany's founder through a restructured agreement that reinforces continuity\nand future focus.\n\nAs part of these initiatives, Benedetta I. Casamento has transitioned from\nChair of the Board to Executive Chair. In this expanded role, she will work\nclosely with the management team and the Board of Directors to provide\nstrategic guidance, support execution of the Company’s objectives and help\nposition Milestone Scientific for its next phase of growth and value creation.\n\nThe Company also announced the appointments of Greg Shilling and Kelly Ann\nUlto as independent members of its Board of Directors. Together, they bring\nextensive experience in healthcare technology, finance, corporate governance\nand strategic growth, further strengthening the Board with capabilities\naligned to the Company’s priorities.\n\n\"We have made meaningful progress in advancing our strategic and commercial\nobjectives, and these board enhancements position us well for the next stage\nof the Company’s evolution,\" said Eric Hines, Chief Executive Officer of\nMilestone Scientific. \"Benedetta’s transition to Executive Chair ensures\ncontinuity while enabling even greater strategic engagement with management.\nAt the same time, the addition of Kelly Ulto and Greg Shilling brings highly\nrelevant expertise that strengthens our governance and supports our focus on\ndisciplined execution and innovation.\"\n\nGreg Shilling\n\nMr. Shilling is a seasoned technology executive and entrepreneur with more\nthan 30 years of leadership experience across healthcare technology, software,\ninteroperability, artificial intelligence and cybersecurity. Throughout his\ncareer, Mr. Shilling has advised technology companies on growth strategy,\ninvestment and operational scaling.\n\nHe currently serves as Partner and General Manager of 121G and 10Bridge, where\nhe leads initiatives focused on digital transformation, software development,\ncybersecurity and data interoperability. Previously, he spent more than 17\nyears at Greenway Health in senior executive roles overseeing corporate\ndevelopment, strategic partnerships, enterprise sales and marketing. During\nhis tenure, he contributed to the company’s growth from an early-stage\nhealthcare technology provider to a leading electronic health record software\ncompany, including its involvement in public market activity, private equity\ntransactions, mergers and acquisitions and strategic partnerships. He holds a\nBachelor of Science in Finance from Auburn University.\n\nKelly Ann Ulto, CPA, MBA\n\nMs. Ulto is a Certified Public Accountant with more than 30 years of\nexperience in audit, financial reporting, internal controls and risk\noversight. She began her career at KPMG LLP, where she rose to Senior Manager\nin the Audit practice, leading client audit engagements and evaluating control\nenvironments while working closely with senior leadership and audit\ncommittees.\n\nSince 2004, Ms. Ulto has served as a Clinical Professor at Fordham\nUniversity’s Gabelli School of Business, where she teaches audit, analytics\nand financial reporting. She has maintained an active professional practice\nalongside her academic role, including delivering technical audit training to\nKPMG professionals nationwide for more than 15 years. She has also developed\nfraud detection training for the U.S. Securities and Exchange Commission,\ntrained FINRA examiners in financial accounting and financial statement\nanalysis and contributed to AICPA Industry Guides.\n\nMs. Ulto brings audit committee experience through her service on the Pelham\nUnion Free School District Audit Committee from 2017 to 2025, where she\nparticipated in audit planning, internal control oversight and financial\nreporting review. She previously served as Board Member and Treasurer of the\nPelham Art Center. Ms. Ulto holds an MBA in Information Decision Technology\nfrom Iona University and a Bachelor of Science in Public Accounting from\nFordham University.\n\nFounder Transition and Continued Advisory Role\n\nThe Company also announced that it has entered into a restructured agreement\nwith its founder Leonard (\"Len\") Osser, reflecting a collaborative transition\nthat supports the Company's governance evolution while aligning the interests\nof shareholders and the Company. As founder, former Chief Executive Officer\nand former Board member, Mr. Osser has played a pivotal role in establishing\nMilestone Scientific's vision and advancing its technology platform.\n\n\"We want to thank Len for his vision in founding Milestone Scientific and for\nhis many contributions as our Chief Executive Officer and member of the Board\nof Directors,\" Hines added. \"His leadership helped establish the foundation\nfor the Company and advance the innovative technology that continues to\ndifferentiate us today. We are pleased that Len will continue to support the\nCompany as an advisor and appreciate his willingness to restructure his prior\ncontractual arrangements in a manner that benefits our shareholders and\nprovides the Company with greater flexibility moving forward.”\n\nAdditional details regarding the board appointments and the agreement with Mr.\nOsser are included in the Company’s Current Report on Form 8-K filed with\nthe U.S. Securities and Exchange Commission.\n\nAbout Milestone Scientific Inc.\n\nMilestone Scientific Inc. (MLSS) is a technology-focused medical research and\ndevelopment company that patents, designs, and develops innovative injection\ntechnologies and instruments for medical and dental applications. Milestone\nScientific’s computer-controlled systems are designed to make injections\nprecise, efficient and increase the overall patient comfort and safety. Their\nproprietary DPS Dynamic Pressure Sensing Technology® instruments is the\nplatform to advance the development of next-generation devices, regulating\nflow rate and monitoring pressure from the tip of the needle, through platform\nextensions of subcutaneous drug delivery, including local anesthetic. To learn\nmore, view the MLSS brand video\n(https://www.globenewswire.com/Tracker?data=AI9u3tx5unpMxON3sgE7pFXSRe91g2Kslm8Qw7TrmfsvJWCV4pFAdA4NTrkJI_CK7QmI5JeEPk4214Yx_xBzJg7OofQ5DwuvQ-Aqe0y_-Xsr9j99kn5dEyzx-8ZdfEYaIt4Fyx9LH6xEmYe08Bn0Lg==)\nor visit milestonescientific.com\n(https://www.globenewswire.com/Tracker?data=7jdVnjfGppuK3yMIKoSZTSknJuXZX62NJOjbMTLW26LdV4IvVaYV1oXezaXzvOLUdJs53LfTqdu-ebbK3KZRhSZXCOAxEKMe7ICvlKiHwxOhgB4LGKDXCrFOVC-UsU2a).\n\nSafe Harbor Statement\n\nThis press release contains forward-looking statements regarding the timing\nand financial impact of Milestone’s ability to implement its business plan,\nexpected revenues, timing of regulatory approvals and future success. These\nstatements involve a number of risks and uncertainties and are based on\nassumptions involving judgments with respect to future economic, competitive\nand market conditions, future business decisions and regulatory developments,\nall of which are difficult or impossible to predict accurately and many of\nwhich are beyond Milestone’s control. Some of the important factors that\ncould cause actual results to differ materially from those indicated by the\nforward-looking statements are general economic conditions, failure to achieve\nexpected revenue growth, changes in our operating expenses, adverse patent\nrulings, FDA or legal developments, competitive pressures, changes in customer\nand market requirements and standards, and the risk factors detailed from time\nto time in Milestone’s periodic filings with the Securities and Exchange\nCommission, including without limitation, Milestone’s Annual Report for the\nyear ended December 31, 2025. The forward-looking statements in this press\nrelease are based upon management’s reasonable belief as of the date hereof.\nMilestone undertakes no obligation to revise or update publicly any\nforward-looking statements for any reason. Coding and payment decisions are\ndetermined solely by providers and payers based on applicable laws and\npolicies. Any potential Category I designation is determined solely by the\nAmerican Medical Association and is not guaranteed. Providers remain\nresponsible for compliance with all applicable billing, coding, and regulatory\nrequirements. Forward-looking case submission expectations, reimbursement\ntargets, and revenue estimates referenced herein are based on current program\nenrollment, advisor commitments, and historical payer activity, and are\nsubject to change based on clinical scheduling, payer processing timelines,\nregulatory developments, and other factors. There can be no assurance that\nCategory I designation, targeted reimbursement levels, or projected revenue\nlevels will be achieved.\n\nContact:\n\nHAYDEN IR:\nJames Carbonara\n(646)-755-7412\njames@haydenir.com\n\nBrett Maas\n(646) 536-7331\nbrett@haydenir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/408ad3c5-6ad3-41bd-9763-356666216796)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-25T13:00:00.91415876Z","server_sent_at_ms":1782392400914},"received_at":"2026-06-25T13:00:01.379Z","source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317586/15852/en/Milestone-Scientific-Strengthens-Board-to-Support-Next-Phase-of-Growth.html"},"analysis":{"id":"62645","press_release_id":"73280","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Milestone Scientific appointed Greg Shilling and Kelly Ann Ulto as independent directors, while Benedetta I. Casamento transitioned from Chair of the Board to Executive Chair to strengthen governance and support growth.\n\nShilling brings over 30 years of healthcare technology and software experience, while Ulto adds deep expertise in audit and financial controls, having trained SEC and FINRA examiners.\n\nThe company also restructured its agreement with founder Leonard Osser, who moves to an advisory role, to align shareholder interests and provide greater operational flexibility.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Governance refresh adds healthcare tech and financial expertise to the board."},"keyFigures":null,"quotedText":"We have made meaningful progress in advancing our strategic and commercial objectives, and these board enhancements position us well for the next stage of the Company’s evolution","namedEntities":{"people":[{"name":"Benedetta I. Casamento","role":"Executive Chair"},{"name":"Greg Shilling","role":"Independent Director"},{"name":"Kelly Ann Ulto","role":"Independent Director"},{"name":"Eric Hines","role":"Chief Executive Officer"},{"name":"Leonard Osser","role":"Founder"},{"name":"James Carbonara","role":"Contact"},{"name":"Brett Maas","role":"Contact"}],"products":["DPS Dynamic Pressure Sensing Technology"],"companies":[{"name":"Milestone Scientific Inc.","ticker":"MLSS"},{"name":"121G","relationship":"employer of new director"},{"name":"10Bridge","relationship":"employer of new director"},{"name":"Greenway Health","relationship":"former employer of new director"},{"name":"KPMG LLP","relationship":"former employer of new director"},{"name":"Fordham University","relationship":"employer of new director"},{"name":"U.S. Securities and Exchange Commission","relationship":"regulatory body"},{"name":"FINRA","relationship":"regulatory body"},{"name":"HAYDEN IR","relationship":"Investor Relations"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Governance refresh adding experienced independent directors and restructuring the founder's role. While positive for long-term execution, standard board updates typically do not move the market significantly."},"tickerRelevance":{"others":[],"primary":"MLSS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["executive_change"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"board_change"}},"event_type":"board_change","event_type_secondary":["executive_change"],"sentiment":"bullish","material_impact_score":2,"narrative":"Milestone Scientific appointed Greg Shilling and Kelly Ann Ulto as independent directors, while Benedetta I. Casamento transitioned from Chair of the Board to Executive Chair to strengthen governance and support growth.\n\nShilling brings over 30 years of healthcare technology and software experience, while Ulto adds deep expertise in audit and financial controls, having trained SEC and FINRA examiners.\n\nThe company also restructured its agreement with founder Leonard Osser, who moves to an advisory role, to align shareholder interests and provide greater operational flexibility.","key_figures":null,"named_entities":{"people":[{"name":"Benedetta I. Casamento","role":"Executive Chair"},{"name":"Greg Shilling","role":"Independent Director"},{"name":"Kelly Ann Ulto","role":"Independent Director"},{"name":"Eric Hines","role":"Chief Executive Officer"},{"name":"Leonard Osser","role":"Founder"},{"name":"James Carbonara","role":"Contact"},{"name":"Brett Maas","role":"Contact"}],"products":["DPS Dynamic Pressure Sensing Technology"],"companies":[{"name":"Milestone Scientific Inc.","ticker":"MLSS"},{"name":"121G","relationship":"employer of new director"},{"name":"10Bridge","relationship":"employer of new director"},{"name":"Greenway Health","relationship":"former employer of new director"},{"name":"KPMG LLP","relationship":"former employer of new director"},{"name":"Fordham University","relationship":"employer of new director"},{"name":"U.S. Securities and Exchange Commission","relationship":"regulatory body"},{"name":"FINRA","relationship":"regulatory body"},{"name":"HAYDEN IR","relationship":"Investor Relations"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-25T13:26:48.174Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"board_change"}},"durationMs":118963,"modelName":"george-droid-qwen-72b"}}